Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium.
Fan R, et al. Among authors: xie q.
Gut. 2016 Feb;65(2):313-20. doi: 10.1136/gutjnl-2014-308546. Epub 2015 Jan 13.
Gut. 2016.
PMID: 25586058
Free PMC article.
Clinical Trial.